HRT prescribing online has become one of the highest-volume telehealth categories in the UK since 2022, driven by the NICE NG23 update and the introduction of the NHS HRT-PPC. The clinical questions are nuanced, the supply situation is improving, and the regulatory expectations have tightened. This piece is a plain-English guide for clinicians and brands operating in HRT.
The HRT market in the UK — patient demand, supply, NHS HRT-PPC
Patient demand for HRT has grown significantly since 2022. The NHS HRT-PPC, introduced in April 2023, provides annual prescription cover for HRT at a current rate around £19.30 per year, materially shifting some demand to the NHS route. Private demand remains strong for specialist preparations and faster access.
What can and cannot be assessed asynchronously
Routine HRT initiation in low-risk patients can be assessed asynchronously where clinical history is clear and red-flag pathways are robust. Complex perimenopausal symptoms, atypical presentations, and patients with significant comorbidities require synchronous consultation or in-person assessment. NICE NG23 sets out clinical guidance for menopause diagnosis and treatment in UK practice.
Red-flag pathways — when an online consultation should escalate
Red flags include: unexplained postmenopausal bleeding, breast symptoms, family history of hormone-sensitive cancers, history of VTE, severe migraines with aura, abnormal liver function, and any presentation that suggests the patient's symptoms have a non-menopausal cause. Robust escalation to in-person assessment is non-negotiable.
Compounded HRT — testosterone for women, body-identical formulations
Testosterone for women in HRT is currently off-label in the UK and requires careful prescribing rationale. Compounded body-identical formulations are dispensed under MHRA Specials regulations where the licensed alternatives do not meet the patient's need. Prescriber discretion applies.
Patient monitoring on long-term HRT — record-keeping
Annual review of HRT prescribing is recommended by NICE and most clinical pathways. Records should include symptom response, side effects, blood pressure, BMI, and any new medical history. Compounded preparations require additional documentation around batch and dose justification.
Common compliance pitfalls in HRT advertising
ASA and MHRA both scrutinise HRT advertising closely. Compliance pitfalls include: efficacy claims that overstate evidence, comparative claims against NHS provision, condition-led marketing implying universal applicability, and testimonial-based claims without substantiation. The same CAP Code Rule 12 framework applies.
The NHS HRT-PPC introduced in April 2023 changed the private-HRT economics. Brands operating in HRT need a clear differentiation story versus the NHS route, not just a marketing one.
Routine HRT can be asynchronous. Complex presentations and red flags cannot.
HRT done well is a long-term clinical relationship, not a transaction. Brands and clinics that treat it that way — with annual reviews, robust documentation, and clear escalation pathways — operate sustainably. The ones that treat it as a one-off prescription create both clinical and regulatory risk.
